Mentor/s
Dr. Kirk Bartholomew
Participation Type
Poster
Abstract
Next generation sequencing (NGS) technology has revolutionized genomic analysis for disease research thus yielding many groundbreaking clinical applications. Quick insight into the genome has allowed pharmaceutical advancements that have transformed cancer care. By identifying the unique oncogenes and biomarkers that are specifically driving a patient’s cancer, a personalized treatment plan can be developed. Each cancer is unique and by administering targeted therapies, that explicitly target oncogenic drivers within tumor cells, rather than general treatment methods such as radiation and chemotherapy, more successful patient outcomes are yielded. Targeted therapies are in no way the be all end all of cancer care, a problem often arises when resistance mutations develop, but this is combatted by creating second-line inhibitors and developing combination therapy treatment plans. Overall, by understanding oncogenes and biomarkers through genomic profiling conducted by next generation sequencing, pharmaceutical companies are able to create better treatment options for patients, such as targeted therapies. The goal of the following presentation is to demonstrate how next generation sequencing has become the greatest tool in the fight against cancer.
College and Major available
Biology
Location
Digital Commons
Start Day/Time
4-24-2020 2:00 PM
End Day/Time
4-24-2020 4:00 PM
Prize Categories
Most Scholarly Impact or Potential, Best Visuals, Most Meaningful
Next-Generation Sequencing: Genomic Profiling Leads to the Advancement of Personalized Cancer Care
Digital Commons
Next generation sequencing (NGS) technology has revolutionized genomic analysis for disease research thus yielding many groundbreaking clinical applications. Quick insight into the genome has allowed pharmaceutical advancements that have transformed cancer care. By identifying the unique oncogenes and biomarkers that are specifically driving a patient’s cancer, a personalized treatment plan can be developed. Each cancer is unique and by administering targeted therapies, that explicitly target oncogenic drivers within tumor cells, rather than general treatment methods such as radiation and chemotherapy, more successful patient outcomes are yielded. Targeted therapies are in no way the be all end all of cancer care, a problem often arises when resistance mutations develop, but this is combatted by creating second-line inhibitors and developing combination therapy treatment plans. Overall, by understanding oncogenes and biomarkers through genomic profiling conducted by next generation sequencing, pharmaceutical companies are able to create better treatment options for patients, such as targeted therapies. The goal of the following presentation is to demonstrate how next generation sequencing has become the greatest tool in the fight against cancer.
Students' Information
Stephanie Castagliuolo, Sacred Heart University '20, Molecular & Cellular Biology Major, Chemistry Minor, Thomas More Honors Program, TriBeta National Biological Honor Society.
Honorable Mention, Best Visuals 2020 award.